CanRIO Recommendations for the Assessment and Management of Rheumatic Immune Related Adverse Events from Cancer Immunotherapy

Coming 2024/2025! With support from the Canadian Rheumatology Association (CRA) Guidelines Committee, CanRIO has assembled a working group of rheumatologists, oncologist and patient representative to present a Canadian perspective on the assessment and management of rheumatic immune related adverse events from cancer immunotherapy as well as patients with pre-existing autoimmune disease and cancer, for which immunotherapy is indicated.